The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

@article{Palladini2010TheCO,
  title={The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.},
  author={Giovanni Palladini and Alessandra Barassi and Catherine Klersy and Rosana Pacciolla and Paolo Milani and Gabriele Sarais and Stefano Perlini and Riccardo Albertini and Paola Russo and Andrea Foli and Letizia Zenone Bragotti and Laura Obici and Remigio Moratti and Gian Vico Melzi d'Eril and Giampaolo Merlini},
  journal={Blood},
  year={2010},
  volume={116 18},
  pages={3426-30}
}
In light-chain (AL) amyloidosis, prognosis is dictated by cardiac dysfunction. N-terminal natriuretic peptide type B (NT-proBNP) and cardiac troponins (cTn) are used to assess the severity of cardiac damage. We evaluated the prognostic relevance of a high-sensitivity (hs) cTnT assay, NT-proBNP, and cardiac troponin I in 171 consecutive patients with AL amyloidosis at presentation and 6 months after treatment. Response and progression of NT-proBNP were defined as more than 30% and more than 300… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 75 extracted citations

Current trends in diagnosis and management of cardiac amyloidosis.

Current problems in cardiology • 2013
View 3 Excerpts
Highly Influenced

Light Chain Amyloidosis

Mediterranean journal of hematology and infectious diseases • 2018

References

Publications referenced by this paper.
Showing 1-10 of 27 references

A phase II trial of cyclophosphamide , lenalidomide and dexamethasone ( CLD ) in previously treated patients with AL amyloidosis [ abstract ]

Gibbs SDJ, PT Sattianayagam, CJ Whelan
2010

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone (CLD) in previously treated patients with AL amyloidosis

P Russo, G Palladini, L Zenone Bragotti
[abstract]. Amyloid • 2010

Role of NT-ProBNP to assess the adequacy of treatment response in AL amyloidosis

A Wechalekar, G Merlini, JD Gillmore
[abstract]. Blood • 2008

Similar Papers

Loading similar papers…